Kaan Harmankaya

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Jedd D. Wolchok, Jeffrey S. Weber, Michele Maio et al. · Annals of Oncology · 2013 · 172 citations · Full text

Medicine, Clinical Sciences, Oncology +16

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

Célèste Lebbé, Jeffrey S. Weber, Michele Maio et al. · Annals of Oncology · 2014 · 142 citations · Full text

Medicine, Clinical Sciences, Oncology +17

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy

Kaan Harmankaya, Christa Erasim, Claus Koelblinger et al. · Medical Oncology · 2010 · 104 citations

Medicine, Oncology, Pharmacotherapy +16

Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.

Katja Schindler, Kaan Harmankaya, Deborah Kuk et al. · Journal of Clinical Oncology · 2014 · 72 citations

Life Sciences, Immunology, Oncology +17